J Surg Oncol 2013 Mar 18;107(4):307-11. Epub 2012 Jul 18.
Department of Surgery, Duke University, Durham, NC 27710, USA.
Background: The treatment of metastatic colorectal cancer (CRC) has evolved rapidly over the last decade, with combination chemotherapy and targeted biologic agents leading to significant improvements in survival. Despite these advances, little is known about their effectiveness in CRC-associated peritoneal carcinomatosis. The purpose of this study was to evaluate outcomes in patients with CRC-associated PC treated in the era of modern chemotherapy. Read More